---
categories: 
- Database
- Release
date: 2025-12-26
title: Database release
github_url: https://github.com/vanallenlab/moalmanac-db/releases/tag/v.2025-12-26
---
This release contains updates to the current and draft versions of the database with FDA precision oncology approvals from October, November, and December 2025. 

## Database content updates
Added entries:
- (FDA) Activating _ERBB2_ TKD variants and sensitivity to sevabertinib for patients with non-squamous NSCLC **(in development version only)**.
- (FDA) HER2 negative and PD-L1 >= 1 and sensitivity to tislelizumab in combination with platinum and fluoropyrimidine-based chemotherapy for patients with gastric or gastroesophageal junction adenocarcinoma **(in development version only)**.
- (FDA) HER2 positive and sensitivity to trastuzumab deruxtecan in combination with pembrolizumab for patients with unresectable or metastatic breast cancer **(in development version only)**.
- (FDA) _NPM1_ p.W288Cfs*12 and sensitivity to revumenib for patients with acute leukemias.
- (FDA) _NPM1_ p.W288Cfs*12 and sensitivity to ziftomenib for patients with acute myeloid leukemia.
- (FDA) PD-L1 >= 1 and sensitivity to tislelizumab in combination with platinum-containing chemotherapy for patients with esophageal squamous cell carcinoma **(in development version only)**.

Revised entries:
- (FDA) _BRCA1/2_ mutated mCRPC and sensitivity to rucaparib received regular approval after receiving accelerated approval in 2020 **(in development version only)**.
